Treon SP - Search Results

1

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.

Treon SP, Yang G, Hanzis C, Ioakimidis L, Verselis SJ, Fox EA, Xu L, Hunter ZR, Tseng H, Manning RJ, Patterson CJ, Sheehy P, Turnbull B. Treon SP, et al. Br J Haematol. 2011 Jul;154(2):223-8. doi: 10.1111/j.1365-2141.2011.08726.x. Epub 2011 May 12. Br J Haematol. 2011. PMID: 21564078 Free article.

2

CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.

Treon SP, Agus TB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC. Treon SP, et al. J Immunother. 2001 May-Jun;24(3):272-9. J Immunother. 2001. PMID: 11394506

3

Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.

Hayashi T, Treon SP, Hideshima T, Tai YT, Akiyama M, Richardson P, Chauhan D, Grewal IS, Anderson KC. Hayashi T, et al. Among authors: treon sp. Br J Haematol. 2003 May;121(4):592-6. doi: 10.1046/j.1365-2141.2003.04322.x. Br J Haematol. 2003. PMID: 12752100 Free article.

4

Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.

Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Treon SP, et al. Ann Oncol. 2004 Oct;15(10):1481-3. doi: 10.1093/annonc/mdh403. Ann Oncol. 2004. PMID: 15367407 Free article. Clinical Trial.

5

Extended rituximab therapy in Waldenström's macroglobulinemia.

Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, Anderson KC, Frankel SR; Waldenström's Macroglobulinemia Clinical Trials Group. Treon SP, et al. Ann Oncol. 2005 Jan;16(1):132-8. doi: 10.1093/annonc/mdi022. Ann Oncol. 2005. PMID: 15598950 Free article. Clinical Trial.

6

Clinical responses to sildenafil in Waldenstrom's macroglobulinemia.

Treon SP, Tournilhac O, Branagan AR, Hunter Z, Xu L, Hatjiharissi E, Santos DD. Treon SP, et al. Clin Lymphoma. 2004 Dec;5(3):205-7. doi: 10.3816/clm.2004.n.029. Clin Lymphoma. 2004. PMID: 15636699

7

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.

Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA. Treon SP, et al. J Clin Oncol. 2005 Jan 20;23(3):474-81. doi: 10.1200/JCO.2005.06.059. J Clin Oncol. 2005. PMID: 15659493 Clinical Trial.

8

CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia.

Hunter ZR, Branagan AR, Manning R, Patterson CJ, Santos DD, Tournilhac O, Dorfman DM, Treon SP. Hunter ZR, et al. Among authors: treon sp. Clin Lymphoma. 2005 Mar;5(4):246-9. doi: 10.3816/clm.2005.n.008. Clin Lymphoma. 2005. PMID: 15794857

9

CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia.

Treon SP, Hunter Z, Barnagan AR. Treon SP, et al. Clin Lymphoma. 2005 Mar;5(4):273-7. doi: 10.3816/clm.2005.n.015. Clin Lymphoma. 2005. PMID: 15794864 Clinical Trial.

10

Characterization of familial Waldenstrom's macroglobulinemia.

Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C, Santos DD, Hatjiharissi E, Xu L, Leleu X, Tournilhac O, Patterson CJ, Manning R, Branagan AR, Morton CC. Treon SP, et al. Ann Oncol. 2006 Mar;17(3):488-94. doi: 10.1093/annonc/mdj111. Epub 2005 Dec 15. Ann Oncol. 2006. PMID: 16357024 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

357 results

Search Page

Filters